TB-500

TB-500 is a synthetic peptide sold online as a research chemical and described as a fragment or equivalent of thymosin beta-4 (Tβ4) — a 43-amino-acid protein naturally found in blood platelets, white blood cells, and most nucleated cells throughout the body. Thymosin beta-4 plays a fundamental role in actin cytoskeleton regulation and is involved in cell migration, wound healing, angiogenesis, and inflammatory modulation. TB-500 is popular in biohacking and athletic recovery communities, where it is frequently stacked with BPC-157.

A critical distinction that most online sources blur: the thymosin beta-4 studied in formal clinical trials — developed as a pharmaceutical by companies such as RegeneRx Biopharmaceuticals — is a precisely characterized, pharmaceutical-grade protein administered under regulated trial conditions. 'TB-500' as sold by peptide vendors is an unlicensed research chemical with no standardized formulation, no FDA oversight of manufacturing, and no clinical trial conducted under that name. The human evidence that exists (Phase I safety studies and small pilot trials) is for the pharmaceutical Tβ4, not for TB-500.

Evidence grade: C. While thymosin beta-4 has a more developed preclinical and early clinical literature than many research peptides, the gap between the pharmaceutical Tβ4 studied in trials and the TB-500 vials sold online is substantial. No randomized controlled trial has established efficacy for any indication in humans.

Thymosin beta-4's primary mechanism involves sequestering actin monomers (G-actin), which regulates actin polymerization dynamics and enables cell migration. This is fundamental to wound healing: it allows keratinocytes, endothelial cells, and fibroblasts to move into injured tissue and begin repair [1]. In preclinical models, Tβ4 has been shown to promote re-epithelialization, collagen deposition, and new blood vessel formation. It also reduces inflammatory cytokines at wound sites and may support cardiomyocyte survival under ischemic stress.

The actin-sequestering property distinguishes Tβ4 from simple growth factors — it acts upstream of multiple repair pathways simultaneously rather than targeting a single receptor. Research has explored applications in dermal wound healing, corneal repair, cardiac ischemia, and neurological injury [1]. Whether the 'TB-500' sold commercially preserves the full activity of the pharmaceutical Tβ4 protein studied in trials is unknown, as the two have not been directly compared in any published study.

The most important framing for TB-500 evidence is the distinction between the compound studied in trials and what is sold online. The human data that exist were generated using pharmaceutical thymosin beta-4 under IND (Investigational New Drug) conditions — not using TB-500 research chemicals. A 2010 Phase I study by Ruff et al. administered intravenous Tβ4 to healthy volunteers in single and multiple doses and found the compound was generally well tolerated, establishing a preliminary human safety profile [3]. A 2021 first-in-human Phase I trial of recombinant human Tβ4 in healthy Chinese volunteers confirmed a generally favorable tolerability signal [4]. Neither study evaluated therapeutic efficacy in patients with injury or disease.

The closest thing to therapeutic human evidence comes from two small studies. Treadwell et al. (2012) reported observations of thymosin beta-4 in dermal wound healing 'in preclinical animal models and in patients,' but this was a case series presented at a conference, not a randomized controlled trial [2]. Guarnera et al. (2010) reported a small pilot of thymosin treatment for venous ulcers with suggestive preliminary findings [6]. A pilot cardiac study by Zhu et al. (2016) used Tβ4 to pretreat autologous endothelial progenitor cells before transplantation in acute myocardial infarction patients — this is indirect (Tβ4 was used ex vivo, not injected directly), and the sample was small [5].

An independent 2026 review in Sports Medicine by Mendias and Awan assessed the evidence for unapproved peptide therapies in musculoskeletal injury and athletic performance and concluded that thymosin beta-4 fragments lack the clinical evidence required to support use recommendations in patients or athletes [7]. No completed, peer-reviewed randomized controlled trial has demonstrated efficacy of TB-500 or thymosin beta-4 for muscle recovery, tendon healing, or sports performance. Evidence grade: C.

No human therapeutic dose has been established for TB-500 through clinical trials. Phase I safety studies of the pharmaceutical Tβ4 used intravenous administration at doses in the range of 6 to 42 mg — regimens that are not directly comparable to the subcutaneous injections sold as TB-500 research chemicals. In the unregulated market, providers and online communities commonly cite doses of 2 to 5 mg injected subcutaneously one to two times per week, sometimes with a higher loading phase for the first several weeks — but these parameters have no validated pharmacokinetic or pharmacodynamic basis in humans.

TB-500 is frequently used in combination with BPC-157 in online recovery protocols. Neither compound has been studied in humans as a standalone or combination therapy in a controlled trial. Both are sold as research chemicals, not as medical products, and neither is legally approved for human therapeutic use in the United States.

The full thymosin beta-4 protein demonstrated acceptable safety in Phase I trials in healthy adult volunteers [3] [4], but several caveats apply: those trials used pharmaceutical-grade, intravenously administered Tβ4 under controlled clinical supervision — not subcutaneously injected research chemicals of unknown purity. Long-term safety in any human population is unknown. Products sold as TB-500 online are not manufactured under FDA Good Manufacturing Practice (GMP) conditions and may contain incorrect doses, incorrect sequences, degraded peptide, or contaminants.

Thymosin beta-4 and its peptide fragments are explicitly listed on the World Anti-Doping Agency (WADA) Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). TB-500 is a banned substance for athletes in all WADA-governed sports. Beyond sports, TB-500 is not FDA-approved for any human indication, and its use outside of a licensed clinical trial is unregulated. Individuals choosing to use it accept unknown risk from a product with no regulatory oversight of its manufacturing or purity.